Advertisement

Advertisement

SGO 2020 Annual Meeting on Women’s Cancer

Gynecologic Cancers

Expert Point of View: Shannon N. Westin, MD, MPH, FACOG

Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, cal...

Gynecologic Cancers

SGO 2020: WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma

Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020...

Gynecologic Cancers

SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?

An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between t...

Gynecologic Cancers

SGO 2020: Updated Data From PRIMA Trial: Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancer

Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three poly (ADP-ribose) polymerase (PARP) inhibitors at th...

Gynecologic Cancers

Expert Point of View: Kathleen N. Moore, MD

Kathleen N. Moore, MD, Associate Professor of Gynecologic Oncology and Director of the Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, Oklahoma City, underscored the importanc...

Gynecologic Cancers

Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?

An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between t...

Gynecologic Cancers

Expert Point of View: Thomas J. Herzog, MD, and Kathleen N. Moore, MD

Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PAOLA-1 trial findings along with updated results of the PRIMA trial, called the diff...

Gynecologic Cancers

Front-Line Maintenance With Olaparib/Bevacizumab Improves Outcomes in Advanced Ovarian Cancer

Proponents of combining bevacizumab with poly (ADP-ribose) polymerase (PARP) inhibition to treat advanced ovarian cancer now have more data to support the maintenance regimen, according to an updated ...

Gynecologic Cancers

Expert Point of View: Thomas J. Herzog, MD

Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PRIMA trial data along with updated results of the phase III PAOLA-1 trial of olapari...

Gynecologic Cancers

Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancers

Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three PARP inhibitors at the European Society for Medical ...

Gynecologic Cancers

Expert Point of View: Shannon N. Westin, MD, MPH, FACOG and Alexander Melamed, MD, MPH

Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, cal...

Gynecologic Cancers

WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma

Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020...

Gynecologic Cancers

Advanced Ovarian Cancer: Use of Neoadjuvant Chemotherapy Increasing Along With Survival

The use of neoadjuvant chemotherapy for advanced ovarian cancer may not have the negative impact on survival feared by many gynecologic oncologists. In fact, according to a pair of studies that were t...

Gynecologic Cancers

SGO 2020: Wee1 Inhibition in Recurrent Uterine Serous Carcinoma

In a clinical trial in patients with recurrent uterine serous carcinoma, one-third of study participants responded to treatment with the Wee1 inhibitor adavosertib, according to data presented by Liu ...

Advertisement

Advertisement



Advertisement